Navigation Links
Karolinska Development: EMEA Recommends Orphan Drug Designation for Acute Myeloid Leukemia Treatment
Date:2/18/2010

STOCKHOLM, February 18, 2010 /PRNewswire/ -- The European Medicines Agency (EMEA) recommends orphan drug status for Aprea's treatment of acute myeloid leukemia (AML). The treatment is currently undergoing a Phase I clinical study and a final decision from the European Commission regarding status is expected in a few weeks. Aprea is part of the Karolinska Development portfolio.

"Aprea is developing a new class of anticancer drugs for the treatment of acute myelogenous leukemia, the most common acute leukemia affecting adults which is currently lacking efficient treatment. An orphan drug status would significantly shorten the development time, lower development costs and, if approved, extend market exclusivity to the benefit of affected patients, Aprea and Karolinska Development," says Conny Bogentoft, CEO Karolinska Development.

Karolinska Development holds 43 percent of the Aprea share capital and votes. For further information about Aprea, please visit http://www.aprea.com.

About Karolinska Development

Karolinska Development manages one of the largest portfolios of life science companies in Europe.

Using a unique, highly cost-efficient business model, the management team guides the commercialization of world-class life science innovations, helping to shape the next-generation pharma industry. Since 2003, Karolinska Development has built a portfolio of some 40 companies; among the company's projects, 12 compounds are undergoing clinical trials. The portfolio also includes a total of 19 potential first-in-class products. http://www.karolinskadevelopment.com

    For more information, please contact:

    Conny Bogentoft, CEO Karolinska Development
    Tel: +46(0)706-88-61-43, e-mail:
    conny.bogentoft@karolinskadevelopment.com

SOURCE Karolinska Development AB


'/>"/>
SOURCE Karolinska Development AB
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Karolinska Development New Share Issue Completed - Raising 380 MSEK (36 MEUR)
2. Karolinska Development Portfolio Company Launches GMP Facility for Particulate Manufacturing
3. Karolinska Institutet to Test Vicals Vaxfectin(R) Adjuvant With Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
4. Karolinska Institute to Test Vicals Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
5. Video: The Looming Crisis in Cancer Drug Development: 97% of Adult Cancer Patients Do Not Take Advantage of Clinical Trial Programs
6. Data Monitoring Committee Recommends Continuation of Phase III Study of StemEx(R), a Cord Blood Stem Cell Product, for Leukemia and Lymphoma
7. Elbit Imaging Announces Data Monitoring Committee Recommends Continuation of Phase III Study of StemEx(R), a Cord Blood Stem Cell Product, for Leukemia and Lymphoma
8. Barclays Wealth Recommends Increasing Exposure to Laggard Sectors Including Consumer Staples, Pharmaceuticals and Telecoms
9. US Expert Panel Recommends the Use of Fractional Exhaled Nitric Oxide (FENO) in the Diagnosis and Management of Asthma
10. RiskMetrics Recommends Taro Shareholders Vote Against Taro Board of Directors
11. PROXY Governance Recommends Against Taros Board and Supports Sun
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
Breaking Medicine News(10 mins):